Edwards Lifesciences has grown steadily over recent years, driven by leadership in transcatheter and surgical heart valve technologies and expansion into new markets. Its 2025 performance features revenue growth of approximately 15.7% year-over-year, although operating income declined by 8.3% as investment and margin pressures mounted. The company’s strong cash flow generation, with free cash flow exceeding $1.3 billion, supports ongoing R&D and disciplined capital returns via share repurchases. Looking ahead, Edwards’ growth depends on product innovation, regulatory approvals, clinical adoption of new therapies, and supply chain stability amid intensifying competition from major players like Medtronic and Abbott.